Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, ImmunityBio Inc’s stock clocked out at $2.4, up 0.42% from its previous closing price of $2.39. In other words, the price has increased by $0.42 from its previous closing price. On the day, 5.83 million shares were traded. IBRX stock price reached its highest trading level at $2.45 during the session, while it also had its lowest trading level at $2.37.
Ratios:
To gain a deeper understanding of IBRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.98 and its Current Ratio is at 4.11.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8. On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2268612096 and an Enterprise Value of 2958550272. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.08. Its current Enterprise Value per Revenue stands at 52.271 whereas that against EBITDA is -10.996.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.15, which has changed by -0.32394367 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $7.48, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -6.63%, while the 200-Day Moving Average is calculated to be -18.82%.
Shares Statistics:
It appears that IBRX traded 8.69M shares on average per day over the past three months and 7452470 shares per day over the past ten days. A total of 915.63M shares are outstanding, with a floating share count of 98.33M. Insiders hold about 89.60% of the company’s shares, while institutions hold 13.19% stake in the company. Shares short for IBRX as of 1755216000 were 75175215 with a Short Ratio of 8.65, compared to 1752537600 on 76978537. Therefore, it implies a Short% of Shares Outstanding of 75175215 and a Short% of Float of 25.83.
Earnings Estimates
A comprehensive evaluation of ImmunityBio Inc (IBRX) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.51 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.29, with 2.0 analysts recommending between -$0.29 and -$0.3.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $31.88M. It ranges from a high estimate of $38.11M to a low estimate of $27.5M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $6.11MFor the next quarter, 5 analysts are estimating revenue of $35.29M. There is a high estimate of $47.64M for the next quarter, whereas the lowest estimate is $30M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $128.7M, while the lowest revenue estimate was $100.44M, resulting in an average revenue estimate of $110.15M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $221.49M in the next fiscal year. The high estimate is $279.4M and the low estimate is $140.83M.
